RIMS binding protein 3CGenealiases: RIM-BP3.3 · RIMBP3.3
Q-omics provides the consensus-scored RIMBP3C profile across patient tissues and cancer cell-line models. RIMBP3C expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RIMBP3C is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, RIMBP3C RNA expression shows 9,593 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LIHC, KIRC, and THYM as cancer lineages where RIMBP3C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RIMBP3C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RIMBP3C survival associations across molecular data types. RIMBP3C RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RIMBP3C RNA expression–survival associations across cancer types. High RIMBP3C expression shows unfavorable associations in LIHC, CHOL and LUAD, but favorable associations in PAAD, THCA and BLCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for RIMBP3C RNA expression.
This table summarizes RIMBP3C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RIMBP3C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RIMBP3C shows lower tumor expression in PAAD and higher tumor expression in KIRC, THCA, BRCA, BLCA and HNSC. The KIRC box plot shows higher RIMBP3C RNA expression in tumor versus normal tissue (log2 FC = +0.041, t-test p < 0.001).
This table shows molecular features associated with RIMBP3C in patient tissues and cancer cell lines. In patient samples, RIMBP3C shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, RIMBP3C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE.
